Cell Reports Medicine最新文献

Hepatocellular carcinoma (HCC) features a tumor immunosuppressive microenvironment (TIME) and limited response to immune checkpoint inhibitors (ICIs). To address this, we develop ultrasound-responsive nanoparticles by encapsulating PD-L1-targeting small interfering RNA (siRNA) and sonodynamic metal-organic frameworks (MOFs) into bacterial membrane vesicles (BMVs) derived from Akkermansia muciniphila. The siRNA-MOF@BMV (SMB) demonstrates HCC-specific accumulation via N-acetylgalactosamine (GalNAc) and induces pyroptosis through NLRP3/Caspase-1/GSDMD pathway activation under ultrasound, releasing tumor antigens. Simultaneously, SMB further induces trained immunity in tumor-associated macrophages (TAMs), promoting CXCL9⁺ phenotypes that enhance antigen presentation and chemotaxis capacity. This increases cytotoxic CD8⁺ T cell infiltration and reduces exhausted T cells, reshaping the TIME. Furthermore, SMB exhibits superior tumor suppression compared to clinical ICIs through systematic evaluations in orthotopic HCC mouse models, primary HCC models, patient-derived xenograft (PDX), and organoid models. SMB presents a multifunctional immunotherapeutic strategy integrating targeted pyroptosis induction, innate immune training, and ICI delivery, representing a potent immunotherapeutic agent for HCC.

In the United States, an estimated 14 million colonoscopies are performed yearly, each requiring patients to undergo bowel preparation, a laxative cleansing of the intestine's luminal contents. Despite its widespread use, the effects of bowel preparation on gut physiology and susceptibility to pathogens remain poorly understood, particularly in individuals with compromised gut health. Using mouse and in vitro models, we find that bowel preparation with the laxative polyethylene glycol rapidly disrupts the gut, transiently increasing susceptibility to infection by Salmonella Typhimurium, including a non-motile mutant, and by gut pathobionts derived from ulcerative colitis microbiota. Bowel preparation also facilitates bacterial translocation to extraintestinal sites (mesenteric lymph nodes, liver, and spleen) and exacerbates inflammation in a chemically induced colitis model. Although these findings are preclinical, they suggest that bowel preparation may have underappreciated risks in vulnerable populations and warrant further clinical investigation.

This study explores the role of efferocytosis in esophageal squamous cell carcinoma (ESCC) using single-cell RNA sequencing and in vitro/in vivo assays. Analyzing 27 samples from 9 patients with ESCC, we identify diverse cell types and significant heterogeneity in the tumor microenvironment, with a focus on efferocytosis. Our findings highlight that macrophages engulf apoptotic tumor cells, thereby impairing immune responses and promoting tumor progression. Notably, TP63 and RAC2 emerge as key regulators of this process, influencing efferocytosis and immune modulation. Functional assays demonstrate that disrupting these pathways alters macrophage efferocytosis and impacts tumor growth in vivo. These results suggest that targeting efferocytosis pathways offers potential therapeutic strategies for ESCC, enhancing antitumor immunity and improving patient outcomes. The study underscores the complex interactions between tumor cells and the immune system, with efferocytosis representing a promising therapeutic target.

DF6215 is a rationally engineered interleukin-2 (IL-2) Fc-fusion protein developed to overcome efficacy and safety limitations of traditional IL-2 cancer immunotherapy. Unlike non-alpha (non-α) IL-2 variants that eliminate CD25 binding and underperform clinically, DF6215 retains moderate IL-2 receptor α (IL-2Rα) affinity while enhancing IL-2Rβγ signaling and extending the half-life via an engineered immunoglobulin (Ig)G1 Fc domain. This design preferentially expands cytotoxic CD8⁺ T cells and natural killer cells over regulatory T cells, resulting in favorable effector-to-regulatory cell ratios, enhanced immune activation, and robust tumor regression in mouse models. In poorly immunogenic tumors, DF6215 synergized with PD-1 blockade to achieve durable responses without added toxicity. Cynomolgus monkey studies confirm DF6215's pharmacodynamics and favorable safety profile, with no signs of vascular leak syndrome or cytokine release syndrome. These findings position DF6215 as a differentiated IL-2 capable of modulating the tumor microenvironment and achieving potent anti-tumor immunity with improved tolerability, supporting its advancement into clinical trials for solid tumors.

Mounting evidence highlights the interplay between gut microbiota, metabolism, and depression. In this study, we analyze fecal and serum metabolomes in first-episode depression and matched controls (n = 186), with validation in three independent cohorts (n = 223, 85, 52) including drug intervention. Significant disruptions are noted in 53 gut microbial species, 12 microbiota-related metabolic pathways, and 34 metabolites in depressive individuals compared to controls. Sixteen metabolites exhibit reversal after drug administration. Partial Spearman analysis identifies 271 species-metabolite correlations, and mediation analysis unveils 61 metabolite-mediated species-depression correlations. Key features associated with depression, including Bifidobacterium longum, Parasutterella excrementihominis, tyrosine, serotonin, and homovanillic acid, are highlighted. A machine learning model with 34 metabolites achieves area under the receiver operating characteristic (ROC) curve values of 0.82 and 0.80 in discriminating depression from control in test and validation sets. Our findings highlight metabolites as key mediators linking microbiota to depression and as valuable indicators for its identification.

Metabolic dysfunction-associated steatotic liver disease (MASLD) remains a prevalent condition with limited diagnostic and therapeutic options. This study aims to identify metabolic signatures of disease progression and develop non-invasive diagnostic models through three independent cohorts (including two cohorts confirmed by biopsy and one cohort confirmed by ultrasound) involving 293 participants for detecting significant fibrosis (≥F2) and mild to severe inflammatory activity (≥I2) using multiple machine learning techniques. The fibrosis panel shows area under the receiver operating characteristic curve (AUROC) of 0.928 (95% confidence interval [CI]: 0.835-0.978), 0.829 (0.732-0.902), and 0.806 (0.724-0.872) in the discovery cohort, validation cohort 1, and validation cohort 2, respectively, outperforming the fibrosis-4 index (FIB-4), aspartate aminotransferase-to-platelet ratio index (APRI), non-alcoholic fatty liver disease fibrosis score (NFS), liver stiffness measurement (LSM), and combination of hoMa, Ast and CK18 (MACK-3). The inflammation panel achieves AUROCs of 0.894 (0.791-0.957) and 0.776 (0.673-0.859) in the discovery cohort and validation cohort 1, respectively. The key metabolites guanidinoacetic acid (GAA) and sebacic acid (SA) demonstrate therapeutic efficacy in mice. These validated panels provide accurate stratification of MASLD severity, and GAA/SA offer therapeutic potential, advancing both diagnosis and treatment strategies.

CRISPR-based gene and cell therapies are rapidly transitioning from experimental platforms to clinical reality, exemplified by the recent approval of CRISPR-derived treatments for β-hemoglobinopathies. This review highlights how advances in genome editing technologies, ranging from CRISPR-Cas nucleases to base and prime editors, are expanding the therapeutic landscape beyond traditional gene knockout approaches. We focus on the clinical translation of these tools, drawing on examples from ongoing and completed human trials to illustrate their potential across diverse disease areas. Furthermore, we discuss critical considerations such as delivery challenges, long-term safety, immune responses, and editing specificity, all of which are critical to the safe and effective integration of CRISPR technologies into modern medicine.

Sepsis, characterized by its complex pathophysiology, presents significant challenges for clinical treatment. An integrative approach combining highly effective antibacterial measures, immunomodulation, and organ protection is urgently needed to enhance the therapeutic efficacy. Here, we construct hybrid cerium-baicalein nanozymes (Ce-BE NZs), which exhibit broad-spectrum non-antibiotic antibacterial and redox enzyme-mimicking activities, effectively scavenging reactive oxygen species and reducing inflammatory mediators in lipopolysaccharide-stimulated macrophages. Ce-BE NZs also correct immune dysregulation, reduce liver injury, and extend survival in both cecal ligation and puncture and "two-hit" sepsis models. Mechanistically, Ce-BE NZs inhibit ferroptosis and mitigate mitochondrial dysfunction by promoting ferritin heavy chain-1 expression, thereby enhancing multi-target sepsis therapy. Additionally, they mitigate ferroptosis and cell damage in a macrophage-incorporating human liver-derived organoid model. Overall, Ce-BE NZs represent a promising multi-target therapy for sepsis and may pave the way for an antibiotic-free and transnational approach to treating other infectious diseases.

HIV-associated neurocognitive disorder (HAND) remains a significant complication in people living with HIV, with inflammation playing a central role in its pathogenesis. Understanding how the brain's immune network responds to lentiviral infection is therefore critical. We show that acute simian immunodeficiency virus (SIV) infection elicits a robust resident brain immune response in control animals, marked by enhanced microglial ramification. In contrast, animals pretreated with anti-interleukin (IL)-15 antibodies (αIL-15) before SIV_mac239X infection display reduced neuroinflammation without altering brain viral burden. Peripheral IL-15 blockade decreases brain-infiltrating T lymphocytes, alters their spatial dynamics, suppresses proinflammatory cytokine (IL-6) expression in microglia, and increases anti-inflammatory cytokine (TGF-β) expression in brain macrophages. Transcriptomic profiling reveals a global reduction in inflammatory signaling and an upregulation of genes associated with M1 macrophage pathways. Together, these findings demonstrate that peripheral IL-15 modulation attenuates neuroinflammation during acute lentiviral infection and highlight IL-15 as a potential therapeutic target for neuroinflammatory conditions of the brain.

Antibody-based therapies have transformed the management of immune-mediated inflammatory diseases (IMIDs), but the need for frequent injections often leads to inadequate patient adherence and suboptimal long-term disease control. To address this challenge, we develop AIDEN (aid for IMIDs: engineered EcN), an engineered probiotic platform that enables oral delivery of therapeutic antibodies using synthetic biology. In this study, we assess the efficacy of AIDEN-IL17, a variant designed to secrete single-chain variable fragments targeting interleukin-17A (IL-17A), in murine models of psoriasis and inflammatory bowel disease. AIDEN-IL17 exhibits stable gut colonization and sustained in situ antibody production, resulting in moderate reduction of systemic IL-17A levels and significant amelioration of disease symptoms. Notably, the AIDEN platform is modular and adaptable for delivering a broad range of antibody therapeutics, offering a promising, patient-friendly strategy for the treatment of IMIDs.